Rapidly resolved IgG4-related retroperitoneal fibrosis after steroid pulse therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Retroperitoneal fibrosis (RF) is a disorder characterized by the presence of a retroperitoneal mass and concurrent systemic inflammation. Some cases of RF are recognized as belonging to the spectrum of immunoglobulin G4-related disease (IgG4-RD). Glucocorticoids are highly effective for treatment of retroperitoneal fibrosis, although the optimal dose and duration of therapy have not been established. An initial dose of prednisone (40-60 mg) daily is usually administered with a tapering scheme. We report on a 55-year-old man diagnosed with IgG4-related RF and successfully treated with a 3-day course of daily 250 mg (4 mg/kg) intravenous methylprednisolone, which resulted in the prompt resolution of urinary obstruction and systemic symptoms.
Abstract
Retroperitoneal fibrosis (RF) is a disorder characterized by the presence of a retroperitoneal mass and concurrent systemic inflammation. Some cases of RF are recognized as belonging to the spectrum of immunoglobulin G4-related disease (IgG4-RD). Glucocorticoids are highly effective for treatment of retroperitoneal fibrosis, although the optimal dose and duration of therapy have not been established. An initial dose of prednisone (40-60 mg) daily is usually administered with a tapering scheme. We report on a 55-year-old man diagnosed with IgG4-related RF and successfully treated with a 3-day course of daily 250 mg (4 mg/kg) intravenous methylprednisolone, which resulted in the prompt resolution of urinary obstruction and systemic symptoms.
참고문헌 (13)
- Pipitone N, "Retroperitoneal fibrosis", Best Pract Res Clin Rheumatol, 26, pp.439~448 (2012)
- Vaglio A, "Retroperitoneal fibrosis", Lancet, 367(9506), pp.241~251 (2006)
- Vaglio A, "Autoimmune aspects of chronic periaortitis", Autoimmun Rev, 5, pp.458~464 (2006)
- Stone JH, "IgG4-related disease", N Engl J Med, 366, pp.539~551 (2012)
- Harreby M, "Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs", Scand J Urol Nephrol, 28, pp.237~242 (1994)
- Obrencević K, "Mycophenolate mofetil combined with steroids: new experiences in the treatment of idiopathic retroperitoneal fibrosis", Vojnosanit Pregl, 64, pp.385~390 (2007)
- Parker BJ, "High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus", Lupus, 16, pp.387~393 (2007)
- Franchin G, "Pulse steroids: how much is enough?", Autoimmun Rev, 5, pp.111~113 (2006)
- 김현우, "고용량 스테로이드로 치유된 후복막 섬유증식증 2예", Kidney Research and Clinical Practice, 24(6), pp.1017~1021 (2005), 대한신장학회
- Fry AC, "Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis:a retrospective study", Nephron Clin Pract, 108, pp.c213~c220 (2008)
- Mackworth-Young CG, "A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus", Ann Rheum Dis, 47, pp.496~502 (1988)
- Feduska NJ, "Reversal of renal allograft rejection with intravenous methylprednisolone “pulse” therapy", J Surg Res, 12, pp.208~215 (1972)
- Rose BD., "Pathophysiology of renal disease", pp.251~ (1987), McGraw-Hill